Company: BLRX
Filing Date: 2025-01-07
Form Type: 424B5
Source: 0001178913-25-000045
Chunk: 31

Company: BioLineRx Ltd.
Filing Date: 2025-01-07
Form: 424B5
Chunk 31
---
 same amount and kind of securities, cash or property as it would have been entitled to receive upon the occurrence of such Fundamental Transaction if it had been, immediately prior to such Fundamental Transaction, the holder of the number of ADSs then issuable upon exercise of the pre-funded warrant, and any additional consideration payable as part of the fundamental transaction. Transferability In accordance with its terms and subject to applicable laws, a pre-funded warrant may be transferred at the option of the holder upon surrender of the pre-funded warrant to us together with the appropriate instruments of transfer and payment of funds sufficient to pay any transfer taxes (if applicable). Fractional Shares No fractional ADSs or ordinary shares will be issued upon the exercise of the warrants. Rather, the number of ADSs to be issued will, at our election, either be rounded up to the nearest whole number or we will pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the exercise price. Exchange Listing There is no established trading market for the pre-funded warrants, and we do not expect a market to develop. We do not intend to apply to list the pre-funded warrants on any securities exchange or other nationally recognized trading system. Without an active trading market, the liquidity of the pre-funded warrants will be limited. No Rights as an ADS holder Except as otherwise provided in the pre-funded warrants or by virtue of the holders’ ownership of ADS or ordinary shares, the holders of pre-funded warrants do not have the rights or privileges of holders of ADSs or our ordinary shares, including any voting rights, until such pre-funded warrant holders exercise their pre-funded warrants. The holders of pre-funded warrants do not have any rights of holders of ADSs until such time as ADSs are acquired, following exercise of pre-funded warrants for ordinary shares and subsequent deposit thereof with the depositary and delivery of ADSs. Governing Law The pre-funded warrants are governed by New York law. Placement Agent Warrants This summary is subject to and qualified in its entirety by the form of placement agent warrant, which has been provided to the placement agent in this offering. The material terms of the placement agent warrants are substantially the same as those issuable to the investors, as described above, with the exception of the following terms: (a) the exercise price of the placement agent warrants is $0.25 per ADS, (b) the beneficial ownership limitation is 4.99%, (c) holders of placement agent warrants are not entitled to receive cash dividends or distribution or return of capital in the form